Dr. Jesus G. Berdeja, MD

Dr. Berdeja practices at Tennessee Oncology in Nashville, Tennessee.

Dr. Berdeja's NPI, 1902842412, was assigned on June 22, 2006. Dr. Berdeja holds Tennessee license 43220.

Dr. Berdeja's primary practice is Tennessee Oncology, at 393 Wallace Rd, Nashville, TN 37211 in Davidson County. The practice phone is (615) 329-0570.

Dr. Berdeja's primary practice is Tennessee Oncology in Nashville, Tennessee. Dr. Berdeja is also affiliated with Ascension Saint Thomas Hospital West. The medical group on file is Tennessee Oncology. Dmand AI also links Dr. Berdeja to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Berdeja practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Berdeja's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Berdeja is licensed in Tennessee.

CMS data shows 35,671 Medicare services from Dr. Berdeja across 41 procedure codes in 2024, for 287 Medicare patients. Medicare paid $1,228,799 for them.

CMS counts 287 Medicare patients who saw Dr. Berdeja in 2024. The largest group is 65 to 74, with 158 patients. 75% of them have high blood pressure, and 65% have high cholesterol. Their average risk score is 2.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Berdeja's median patient age at 68, with 48% women.

In 2024, Dr. Berdeja wrote 735 Medicare Part D claims for 89 patients. 42% of them were for generic drugs. CMS names the drug for 606 of them, across 11 drugs with 11 or more claims each, at $6,726,884 in total drug cost. In 2023, CMS named 456 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Berdeja for performance year 2024, reported as part of a group. Dr. Berdeja accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Berdeja as offering telehealth.

Dmand AI links 66 papers to Dr. Berdeja, published from 2017 to 2025. 2019 was the busiest year, with 10. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Dexamethasone. Dr. Berdeja has published most often in Clin Lymphoma Myeloma Leuk. Dr. Berdeja's most frequent co-authors are Sundar Jagannath, MD, Parameswaran N. Hari, MD and Ajai Chari, MD.

CMS Open Payments shows 562 general payments to Dr. Berdeja from 44 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $96,867. It also lists 109 research payments totaling $322,283 from 2016 to 2024.